Analysts have been eager to weigh in on the Healthcare sector with new ratings on Owens & Minor (OMI – Research Report), Idexx Laboratories (IDXX – Research Report) and CytomX Therapeutics (CTMX – Research Report).
Owens & Minor (OMI)
In a report released today, Stephanie Davis from Barclays maintained a Hold rating on Owens & Minor, with a price target of $23.00. The company’s shares closed last Friday at $18.21.
According to TipRanks.com, Davis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Owens & Minor is a Hold with an average price target of $24.83, which is a 4.1% upside from current levels. In a report issued on April 29, Citi also maintained a Hold rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Idexx Laboratories (IDXX)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Idexx Laboratories, with a price target of $570.00. The company’s shares closed last Friday at $480.60.
According to TipRanks.com, Prasad is a 3-star analyst with an average return of
Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $571.25, which is a 17.6% upside from current levels. In a report issued on May 1, Goldman Sachs also maintained a Buy rating on the stock.
CytomX Therapeutics (CTMX)
In a report released today, Peter Lawson from Barclays assigned a Buy rating to CytomX Therapeutics, with a price target of $3.50. The company’s shares closed last Friday at $4.43.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
CytomX Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.44, which is a -3.9% downside from current levels. In a report released yesterday, Jefferies also upgraded the stock to Buy with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OMI:
